INIS— RADNOSTIX INC

Health CareLife Sciences Tools & Services$34M mkt cap

Metric	FY2025	FY2024	FY2023	FY2022
Revenues	$13.1M-6.0%	$13.9M+13.3%	$12.3M+9.7%	$11.2M
Cost of product	$5.4M+2.2%	$5.3M+7.4%	$4.9M-0.1%	$4.9M
Gross profit	$7.7M-10.9%	$8.6M+17.2%	$7.4M+17.3%	$6.3M
Salaries and contract labor	$4.5M+11.6%	$4.0M-0.3%	$4.0M+18.9%	$3.4M
General, administrative, and consulting	$3.7M-6.9%	$4.0M+13.1%	$3.5M-0.6%	$3.6M
Research and development	$436K-28.6%	$611K+5.8%	$577K+8.2%	$534K
Total operating expenses	$8.7M+0.2%	$8.6M+6.0%	$8.2M+8.8%	$7.5M
Operating profit (loss)	-$956K-13955.8%	$7K+100.9%	-$776K+35.5%	-$1.2M
Other income	$311K+49.5%	$208K+29.8%	$160K-92.4%	$2.1M
Interest income	$77K-37.4%	$122K+55.1%	$79K+730.2%	$10K
Interest expense	-$339K-3.2%	-$329K+0.9%	-$332K+46.0%	-$614K
Total other (expense) income	$48K+2780.2%	$2K+101.8%	-$93K-106.2%	$1.5M
Net income (loss)	-$908K-10690.2%	$9K+101.0%	-$869K-386.6%	$303K
Net income (loss) per common share - basic: (in dollars per share)	$0.00	$0.00	$0.00	$0.00
Net income (loss) per common share - diluted: (in dollars per share)	$0.00	$0.00	$0.00	$0.00
Weighted average common shares outstanding - basic (in shares)	526.8M+0.9%	522.3M+0.9%	517.8M+1.4%	510.8M
Weighted average common shares outstanding - diluted (in shares)	526.8M+0.9%	522.3M+0.9%	517.8M+1.4%	510.8M

Source: SEC EDGAR XBRL. % change vs prior period shown where available.

Pro feature

Unlock 12 more years of annual history and full quarterly detail on Pro.

Source: SEC EDGAR 10-K and 10-Q filings. Last 4 years annual and quarterly free, full history (up to 20 years) on Pro.